# 4D MOLECULAR THERAPEUTICS IN (FDMT)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/FDMT/

- Reporting holders: 5
- Reported value: $70.1K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [TOTH FINANCIAL ADVISORY CORP](https://holderbook.com/funds/866780-toth-financial-advisory-corp/) | $28.6K | 2,000 | 0.0% | 1 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $22.1K | 1,543 | 0.0% | 12 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $10.4K | 728 | 0.0% | 5 |
| [Planning Strategies Inc.](https://holderbook.com/funds/2139665-planning-strategies-inc/) | $7.2K | 502 | 0.0% | 2 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $1.8K | 125 | 0.0% | 6 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 5 | $70.1K |
| Q2 2026 | 163 | $835.3M |
| Q1 2026 | 149 | $473.6M |
| Q4 2025 | 152 | $403.1M |
| Q3 2025 | 134 | $350.1M |
| Q2 2025 | 120 | $150.8M |
| Q1 2025 | 125 | $140.2M |
| Q4 2024 | 144 | $263.9M |
| Q3 2024 | 138 | $637.3M |
| Q2 2024 | 143 | $1.2B |
| Q1 2024 | 150 | $1.9B |
| Q4 2023 | 112 | $909.1M |